EGFR and non-small cell lung carcinoma: The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as erlotinib and gefitinib, in the treatment of advanced NSCLC has been shown to markedly improve survival, particularly in patients with EGFR-activating mutations which are more common in patients of Asian ethnicity [9].